DiscoverNational Pharmaceutical Congress (NPC) PodcastS14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics
S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

Update: 2025-07-10
Share

Description

Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator’s Award, and earlier detection for ALS.



Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe
Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

S14 E02 Developing Disease Modifying Therapeutics for ALS at Neuropeutics

Jeremy Visser